Business
CFN Insider explores how the U.S. cannabis industry is evolving and the potential impact of a DEA decision to reschedule the drug or its cannabinoid constituents with a leading market analyst and group of five legal experts. In addition, investment opportunities are identified that may arise from these changes. In this episode, we take a look at some of the latest developments: FDA Approves GW Pharma's Epidolex Impact on rescheduling cannabis and DEA's rescheduling possibilities (isolate vs. cannabis plant) Resulting investment plays (cannabinoid drug developers, hemp extracts) Legalization Roundtable: State cannabis programs are flourishing (on both coasts) and fairing well under the Trump Administration on a macro level in light of the Cole Memo rescission, but federal restraints persist Guests on the podcast include: Matt Karnes, Greenwave Advisors Rod Kight, Kight Law Seth Goldberg, Duane Morris LLP Silvia San Nichols, CEO of New Game Compliance Justin Hobson, Lane Powell